Media

Carisma Therapeutics Closes Merger with Sesen Bio

Targovax to prioritize resources on unlocking the potential of its circRNA platform

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Hemab Therapeutics’ Statement Announcing the Planned Departure of Co-Founder and CTO Johan Faber

Year-end report 2022

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results

HealthCap Portfolio Company Hemab Therapeutics raises $135M Series B Financing